SCHEMBL6432253

SCHEMBL6432253

NN=C(c1ccc(-c2ccc(Cl)c(C(=O)O)c2)o1)c1nc2nonc2nc1Nc1ccc(F)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPA1 P27694 1/20 0.44
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
MAPT P10636 4/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
GAA P10253 2/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
XDH P47989 1/20 0.37
SLC22A12 Q96S37 1/20 0.37
C3AR1 Q16581 1/20 0.36
CSNK2A1 P68400 6/20 0.35
CSNK2A2 P19784 2/20 0.35
CSNK2B P67870 2/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6422204 0.94 KDM4E (0.44) RPA1ALDH1A1KDM4EMAPTPOLB
SCHEMBL6433045 0.92 KDM4E (0.45) RPA1ALDH1A1KDM4EMAPTPOLB
SCHEMBL6414872 0.90 RPA1 (0.43) RPA1ALDH1A1KDM4EMAPTPOLB
SCHEMBL6415140 0.90 MAPT (0.42) ALDH1A1KDM4EMAPTPOLBMEN1
SCHEMBL6435669 0.89 MAPT (0.44) ALDH1A1KDM4EMAPTPOLBMEN1
SCHEMBL6416006 0.89 MAPT (0.42) ALDH1A1KDM4EMAPTPOLBMEN1
SCHEMBL6415997 0.89 MAPT (0.42) ALDH1A1KDM4EMAPTPOLBMEN1
SCHEMBL6415959 0.88 BIRC5 (0.42) RPA1ALDH1A1KDM4EMAPTPOLB
SCHEMBL6416293 0.87 ALDH1A1 (0.41) RPA1ALDH1A1KDM4EMAPTPOLB
SCHEMBL6415096 0.85 AURKA (0.38) RPA1ALDH1A1MAPTPOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 RPA1 3166/4885ALDH1A1 1119/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.